Reviva Pharmaceuticals Holdings, Inc. RVPH 深 沪
等待开盘 02-07 09:30:00 美东时间
0.2865
+0.032
+12.35%
华盛通- 最 高0.39
- 今 开0.2598
- 成交量 325.22万股
- 最 低 0.25
- 昨 收 0.255
- 总市值 4335.69045
- 52周最高 0.39
- 市盈率 静 --
- 换手率 21490.59%
- 52周最低 0.00
- 委 比 -57.48%
- 总股本 1.51万
- 历史最高 0.39
- 量 比 1.92
- 振 幅 54.90%
- 历史最低 0.00
- 每 手 1
- 风险率 0.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多US Stocks Mixed; GDP Growth Tops Expectations
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around...
2025-12-23 23:01
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Reviva Pharmaceuticals' Phase 3 RECOVER OLE study of brilaroxazine for schizophrenia demonstrates sustained broad-spectrum efficacy over 1 year, with low adverse events and a 35% discontinuation rate. Positive results across symptom domains, enhanced by improved neuroinflammatory markers, highlight its potential to address unmet needs in schizophrenia treatment.
2025-06-02 11:00
EF Hutton Initiates Coverage On Reviva Pharmaceuticals with Buy Rating, Announces Price Target of $15
EF Hutton analyst Jason Kolbert initiates coverage on Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy rating and announces Price Target of $15.
2024-09-23 20:36
Reviva To Host Virtual KOL Event To Discuss Vocal Biomarker Data From Phase 3 RECOVER Trial Of Brilaroxazine In Schizophrenia On September 4, 2024
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced it will host a v...
2024-08-27 20:06
Benchmark Reiterates Speculative Buy on Reviva Pharmaceuticals, Maintains $17 Price Target
Benchmark analyst Bruce Jackson reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Speculative Buy and maintains $17 price target.
2024-08-26 21:55
Reviva Pharmaceuticals Holdings Prices $5 Million Offering
07:05 AM EDT, 08/21/2024 (MT Newswires) -- Reviva Pharmaceuticals (RVPH) said Wednesday it had priced a $5 million offering of 4.8 million shares of common stock and 4.8 million warrants at a combined price of $1.05. The company said the warrants have an exercise price of $0.7964 per share, exercisa...
2024-08-21 19:05
